17
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Deferoxamine (Desferal)R—Induced Ocular Toxicity

, , , , &
Pages 293-297 | Received 03 Mar 1988, Accepted 03 Mar 1988, Published online: 09 Jul 2009

References

  • Sephton-Smith R. Iron excretion in thalassemia major after administration of chelating agents. Br Med J 1962; 2: 1577–1580
  • Graziano JH, Markerson A, Miller D R., et al. Chelation therapy in B-thalassemia major. Intravenous and subcutaneous deferoxamine. J Pediatr 1978; 92: 648–652
  • Modell B. Advances in the use of iron-chelating agents for the treatment of iron overload. Prog Hematol 1979; 11: 267–312
  • Estrov Z, Awas A, Wang Xin-Hua, et al. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 1987; 69: 757–761
  • Goodman LS, Gilman A. The Pharmaceutical Basis of Therapeutics, 6th ed, A. G. Gilman, L. S. Goodman, A. Gilman. McMillan, New York 1980; 16: 33–34, 1980
  • Batley R, Scott J, Jain S, Sherlock S. Acute renal insufficiency occurring during intravenous deferoxamine therapy. Scand J Haematol 1979; 22: 277–279
  • Bloomfield SL, Markerson AL, Miller, DR, Peterson CM. Lens opacities in thalassemia. J Pediatr Ophthalmol Strabismus 1978; 15: 154–156
  • Davis SC, Marcu RE, Hungerford JL, et al. Ocular toxicity of high-dose intravenous deferoxamine. Lancet 1983; ii: 181–184
  • Lakhaupal V, Schocket SS, Jiji R. Deferoxamine (Desferal)-induced toxic retinal pigmentary pigmentation and preferred optic neuropathy. Opthalmology 1984; 91: 443–451
  • Rubinstein M, Dupont P, Doppee JP, Dehon C, Docubo J, Halnaut J. Ocular toxicity of deferoxamine. Lancet 1983; ii: 512–513
  • Blake, Dr, Winyard P, Lunecf J, et al. Cerebral and ocular toxicity induced by deferoxamine. J Med 1985; 345–355
  • Orton RB, de Veber LL, Sulh H MB. Ocular and auditory toxicity of long-term high-dose subcutaneous deferoxamine therapy. Can J Ophthalmol 1985; 20(4)153–156
  • Bourneris F, Monnier N, Dufier JL, Reveillaud RJ. toxicite oculaire severe de la deferoxamine chez l'hemodialyse. Nephrolgie 1987; 8: 27–29
  • Borgna-Pignatti C, De Stefano P, Broglia AM. Visual loss in patient on high-dose subcutaneous deferoxamine. Lancet 1984; i: 681
  • Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314: 869–873
  • Black, Dr, Hall ND, Bacon PA, Dieppe PA, Halliwell B, Gutteridge J MC. Effects of a specific iron-chelating agents on animal models of inflammation. Am Rheum Dis 1983; 42: 89–93
  • Fliester SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res 1983; 22: 79–131
  • Lederman HM, Cohen A, Lee J WW, Freedman MH, Gelfand WE. Deferoxamine: A reversible S-phase inhibitor of human lymphocytes proliferation. Blood 1984; 64: 748–753
  • Kaplinsky C, Estrov Z, Freedman MH, Gelfand EW, Cohen A. Effect of deferoxamine in DNA synthesis, DNA repair, cell proliferation and differentiation of HL-60 cells. Leukemia 1987; 1: 437–441
  • Ridgway E, Jaffee N, Watton DS. Leukemic ophthalmopathy in children. Cancer 1976; 38: 1744–1749
  • Ha K, Kanaya S, Ikeda T, Ushio T, Nalcao Y, Yabuchi H. Cortical blindness in a child with acute leukemia. Acta Pediatr Scand 1980; 69: 781–782
  • Patchell RA, White CL, Clark AW, Beschormer WE, Sautes GW. Neurologic complications of bone marrow transplantation. Neurology 1985; 35: 300–306

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.